Last reviewed · How we verify
Maintenance of the current regimen
Maintenance of the current regimen is a Small molecule drug developed by Hospital do Rim e Hipertensão. It is currently FDA-approved for Maintenance therapy for unspecified chronic condition(s). Also known as: Myfortic, Immuran.
Continuation of an existing therapeutic regimen without modification to maintain current clinical stability and treatment efficacy.
Continuation of an existing therapeutic regimen without modification to maintain current clinical stability and treatment efficacy. Used for Maintenance therapy for unspecified chronic condition(s).
At a glance
| Generic name | Maintenance of the current regimen |
|---|---|
| Also known as | Myfortic, Immuran |
| Sponsor | Hospital do Rim e Hipertensão |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This represents a clinical decision to maintain a patient's current medication regimen rather than initiate a new drug. The specific mechanism depends entirely on the drugs already being administered. This is a management strategy rather than a pharmacological intervention.
Approved indications
- Maintenance therapy for unspecified chronic condition(s)
Common side effects
Key clinical trials
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Evaluation of the Impact of Reduced Immunosuppression
- Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial. (PHASE4)
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease (PHASE3)
- Safety and Potency of a High Cabergoline Dosage in Microprolactinomas (PHASE3)
- Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy (PHASE3)
- Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maintenance of the current regimen CI brief — competitive landscape report
- Maintenance of the current regimen updates RSS · CI watch RSS
- Hospital do Rim e Hipertensão portfolio CI
Frequently asked questions about Maintenance of the current regimen
What is Maintenance of the current regimen?
How does Maintenance of the current regimen work?
What is Maintenance of the current regimen used for?
Who makes Maintenance of the current regimen?
Is Maintenance of the current regimen also known as anything else?
What development phase is Maintenance of the current regimen in?
Related
- Manufacturer: Hospital do Rim e Hipertensão — full pipeline
- Indication: Drugs for Maintenance therapy for unspecified chronic condition(s)
- Also known as: Myfortic, Immuran
- Compare: Maintenance of the current regimen vs similar drugs
- Pricing: Maintenance of the current regimen cost, discount & access